Close Menu

NEW YORK – Fluidigm said on Monday that it is collaborating with a consortium of medical schools led by the Icahn School of Medicine at Mount Sinai to develop an epigenetic test on Fluidigm's microfluidics platform for early detection of infection with the novel coronavirus and COVID-19 development.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.